Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025Blood

CAR-hematotox score for predicting outcomes among myeloma patients receiving BCMA targeting CART constructs (ide-cel and cilta-cel)

View Full Paper
Ask AI
Bookmark
Share

Authors

ANAjay K. NookaNJNisha S. Joseph

Discussion

Loading...

Member takes

Overview

Evaluation reveals CAR-HEMATOTOX score predicts day 100 and 365 mortality in myeloma patients, suggesting refinement with biomarkers may enhance outcomes.

Key Points

  • To assess the predictive value of CAR-HEMATOTOX score for outcomes in myeloma patients treated with BCMA targeting CART constructs.
  • Evaluated outcomes in 247 myeloma patients treated with Ide-cel and Cilta-cel BCMA CART constructs.
  • Patients were grouped into three cohorts based on treatment type: research and two commercial constructs.
  • Examined the relationship between CAR-HEMATOTOX score and key outcomes like mortality and survival rates.
  • HThigh group showed significantly higher day 100 and day 365 mortality compared to HTlow.
  • Overall median progression free survival was 37.78 months among patients analyzed, with notable differences based on scores.
  • Biomarkers including ferritin and B2-microglobulin were evaluated for their impact on mortality risk.

Cite This Study

Nooka et al. (2025) studied this question.

synapsesocial.com/papers/69362f574fa91c937236daa3https://doi.org/10.1182/blood-2025-4078
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Management of hematological toxicities after BCMA-directed CAR-T cell therapy2026 · 2 citations
  2. 2Late immune effector cell-associated hematotoxicity (ICAHT) in patients with relapsed refractory large B-cell lymphoma receiving anti-CD19 chimeric antigen receptor T-cell therapy2025
  3. 3The prognostic value of CAR-hematox in predicting toxic events in patients with relapsed refractory B cell lymphoma receiving 7x19 CAR-T treatment2025
  4. 4CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma2021 · 478 citations
  5. 5Evaluating the CAR-hematotox score in patients with refractory-relapsed multiple myeloma treated with bispecific T-cell engager therapy2025